Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $636.54 million. The enterprise value is $376.92 million.
| Market Cap | 636.54M |
| Enterprise Value | 376.92M |
Important Dates
The last earnings date was Monday, November 11, 2024, after market close.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 49.77 million shares outstanding. The number of shares has increased by 67.83% in one year.
| Current Share Class | 49.77M |
| Shares Outstanding | 49.77M |
| Shares Change (YoY) | +67.83% |
| Shares Change (QoQ) | +0.93% |
| Owned by Insiders (%) | 2.57% |
| Owned by Institutions (%) | 56.61% |
| Float | 27.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.70 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.55
| Current Ratio | 8.55 |
| Quick Ratio | 8.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.19% and return on invested capital (ROIC) is -42.01%.
| Return on Equity (ROE) | -61.19% |
| Return on Assets (ROA) | -38.55% |
| Return on Capital (ROIC) | -42.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.47M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +58.89% |
| 50-Day Moving Average | 13.02 |
| 200-Day Moving Average | 12.61 |
| Relative Strength Index (RSI) | 53.38 |
| Average Volume (20 Days) | 183,081 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -168.35M |
| Pretax Income | -90.80M |
| Net Income | -153.25M |
| EBITDA | n/a |
| EBIT | -168.35M |
| Earnings Per Share (EPS) | -$3.33 |
Balance Sheet
| Cash & Cash Equivalents | 263.60M |
| Total Debt | n/a |
| Net Cash | 263.60M |
| Net Cash Per Share | $5.30 |
| Equity (Book Value) | 236.93M |
| Book Value Per Share | 4.76 |
| Working Capital | 236.41M |
Cash Flow
In the last 12 months, operating cash flow was -$128.45 million and capital expenditures -$96,000, giving a free cash flow of -$128.55 million.
| Operating Cash Flow | -128.45M |
| Capital Expenditures | -96,000 |
| Free Cash Flow | -128.55M |
| FCF Per Share | -$2.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -67.83% |
| Shareholder Yield | -67.83% |
| Earnings Yield | -23.93% |
| FCF Yield | -20.07% |
Analyst Forecast
The average price target for MLYS is $30.00, which is 134.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 134.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |